title: [Transfusion of plasma: products-indications].
abstract: The use of therapeutic plasma has increased in France by more than 40% since 2002. This growth may be explained by the improvement in transfusion safety, the diminution of the risk of transmission of pathogens and the regained confidence of the physicians in blood products. Therapeutic plasma also benefits from additional procedures to reduce infectious (securisation) or immunological risks (selection of blood donors). Its application in massive transfusions has undergone a significant evolution over the last few years. A proactive attitude favouring early and important use of plasma on the basis of pre-established protocols is advocated henceforth. The prescription of therapeutic plasma for other indications must be guided by the results of biological tests and an evaluation of the haemorrhagic risk. Despite regular updating of the guidelines for good transfusion practice, plasma is still sometimes prescribed for prophylactic purposes in situations where the biological and/or clinical criteria do not justify it. Moreover, it is not recommended to use fresh frozen plasma in cases of deficiency of coagulation factors if the specific concentrates are available as intravenous fluids. Complementary clinical studies will be necessary to evaluate, in certain indications, the real benefits of the transfusion of plasma and the interest of replacing it by concentrates of coagulant factors (fibrinogen, prothrombin complex).
authors.affiliation: EFS Alsace, BP 36, 10, rue Spielmann, 67065 Strasbourg cedex, France. rachid.djoudi@efs-alsace.fr
authors.forename: R
authors.initials: R
authors.lastname: Djoudi
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects; D016913:Blood Component Transfusion; D016063:Blood Loss, Surgical; D006348:Cardiac Surgical Procedures; D020147:Coagulation Protein Disorders / Q000628:therapy; D004211:Disseminated Intravascular Coagulation / Q000628:therapy; D006470:Hemorrhage / Q000139:chemically induced / Q000628:therapy; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000628:therapy; D017093:Liver Failure / Q000628:therapy; D016031:Liver Transplantation; D010949:Plasma; D010951:Plasma Exchange; D019106:Postoperative Hemorrhage / Q000628:therapy; D057049:Thrombotic Microangiopathies / Q000628:therapy
chemical_list: D000925:Anticoagulants